相关实验视频

Updated: Apr 30, 2026

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

Published on: August 3, 2011

多原子数据集成揭示了皮肤纤维化药物点

Zexin Zhang¹, Shu Li², Xinyue Dai¹

¹Department of Plastic Surgery, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Current medicinal chemistry

|July 25, 2025

概括

这项研究确定了NUDT2和PARK7作为治疗状体和缩性痕的关键药物标. 这些发现为痕治疗提供了新的治疗途径,可能通过局部和全身管理.

科学领域:

皮肤病学和分子生物学
遗传学和基因组学遗传学和基因组学
药理学和治疗学药理学和治疗学

背景情况:

痕异质性包括正常痕 (NS),高性痕 (HS) 和 keloids.
痕形成是系统免疫和局部组织微观环境之间的复杂相互作用的结果.
准痕亚型需要了解病变发生的系统和局部维度.

研究的目的:

为了确定痕管理的新型,亚型特定的药物标.
研究潜在治疗点在痕形成中的系统和局部作用.
用多层次的OMIC数据验证已识别的目标.

主要方法:

两个样本的门德尔随机化 (MR) 研究在系统,局部和单细胞水平上进行.
使用DECODE,EQTLGen,GTEx,ScQTLbase和FinnGen数据库进行暴露和结果变量.
采用了七种MR方法和单细胞RNA测序用于目标验证和功能分析.

主要成果:

确定了八个潜在的药物标,NUDT2与胆固醇显著相关,PARK7与HSs相关.
在血液,皮肤和单细胞水平上,NUDT2和PARK7的表达与 keloids 和 HSs 有正相关.
功能分析将NUDT2与血管生成和PARK7与细胞外矩阵组织联系起来.

结论:

NUDT2和PARK7分别是胆固醇和HS的有前途的治疗点.
这些发现支持了痕管理的局部和全身药物输送潜力.
建议进行进一步的多民族研究,以确认目标的普遍性.

关键词:

伤口伤口伤口伤口伤口毒品目标是毒品的目标.门德尔的随机化. 门德尔的随机化.多种主题的多种主题.蛋白质组学和转录组学.

更多相关视频

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Using R, Seurat, and CellChat to Analyze a Single-Cell Transcriptomics Dataset of Mouse Skin Wound Healing

Using R, Seurat, and CellChat to Analyze a Single-Cell Transcriptomics Dataset of Mouse Skin Wound Healing

Published on: August 1, 2025

相关概念视频

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...